Clinical Trials
Expanding clinical trial diversity requires ‘showing up’ in the community to build trust
Limiting eligibility criteria, recruiting trusted community messengers and reducing financial burdens can help improve diversity of clinical trial enrollees, a panel of professionals said during a Friends of Cancer Research webinar.
First patients screened in clinical trial of Axpaxli for wet AMD
Ocular Therapeutix announced that the first three participants have received an aflibercept injection in the phase 3 SOL-1 clinical trial of Axpaxli, an axitinib intravitreal implant for wet age-related macular degeneration.
How to get involved in clinical research: Live from Hawaiian Eye, Part 2
In this episode, Dagny Zhu, MD, and Laura Periman, MD, chat with Kendra Hileman on how to get involved in clinical research.
Positive results announced in phase 2b trial of oral narcolepsy drug
Takeda has announced positive topline results from a phase 2b trial evaluating an oral orexin receptor 2 agonist to treat individuals with narcolepsy type 1.
Enrollment complete in phase 3 trial of sozinibercept for wet AMD
Opthea Limited has completed enrollment of its COAST phase 3 clinical trial, a study of sozinibercept in combination with Eylea for wet age-related macular degeneration, the company announced in a press release.
FDA grants breakthrough designation to frontotemporal dementia treatment
The FDA has granted breakthrough therapy designation to latozinemab, an investigational therapeutic designed to block sortilin and elevate progranulin to treat frontotemporal dementia with a progranulin gene mutation.
First patient dosed in second part of trial for AVD-104 to treat geographic atrophy
Aviceda Therapeutics announced the dosing of the first patient in the second part of its phase 2/3 SIGLEC trial investigating AVD-104 to treat geographic atrophy secondary to age-related macular degeneration.
Q&A: Racial disparities in multiple myeloma clinical trials impact quality of results
Racial disparities continue to exist in clinical trials for patients with multiple myeloma. Along with enrollment barriers and the COVID-19 pandemic, patients with multiple myeloma face challenges for enrollment.
Biogen announces discontinuation of Aduhelm
Biogen announced a reprioritization of resources regarding its pipeline of therapeutics to address Alzheimer’s disease, deciding to discontinue development of Aduhelm and choosing to advance Leqembi.
FDA agrees to amend special protocol assessment for trial of Axpaxli in wet AMD
The FDA has agreed to a special protocol assessment agreement modification for Ocular Therapeutix’s phase 3 SOL clinical trial of Axpaxli, an axitinib intravitreal implant for treatment of wet age-related macular degeneration.